CDKN2A and cancer: FoxM1’s strong connection to the known hallmarks of cancer in addition to its extensive and diverse role during tumorigenic development and progression have become apparent in the past decade, thus driving researchers to innovate FoxM1 inhibitors, including the thiazole antibiotics, siomycin A and thiostrepton (70), an ARF-peptide inhibitor (32) and the EGF receptor agonist, gefitinib (71).